RECRUITING

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Talk to us

Conditions

Atopic Dermatitis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Official Title

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Quick Facts

Study Start:2020-11-30
Study Completion:2027-09-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04455906

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female participants ≥6 to 65 yrs of age
  2. 2. Meet AD Standard Diagnostic Criteria
  1. 1. Enrollment in another clinical trial
  2. 2. Hypersensitivity to an agent used for the skin decolonization protocol
  3. 3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
  4. 4. Phototherapy for AD within 4 weeks
  5. 5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
  6. 6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
  7. 7. Bleach baths within 7 days of the first Visit
  8. 8. Use of oral or topical antibiotics within 21 days of the beginning of the study
  9. 9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
  10. 10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
  11. 11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
  12. 12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
  13. 13. Febrile illness at time of visits
  14. 14. Suspected immune deficiency or family history of primary immunodeficiency

Contacts and Locations

Study Contact

Amparito Cunningham, MD. MPH.
CONTACT
857-218-5336
asthma@childrens.harvad.edu
Conor Brockway
CONTACT
857-218-3819
conor.brockway@childrens.harvard.edu

Principal Investigator

Wanda Phipatanakul, MD. MS.
PRINCIPAL_INVESTIGATOR
Boston Children's Hospital

Study Locations (Sites)

Boston Children's Hospital
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Boston Children's Hospital

  • Wanda Phipatanakul, MD. MS., PRINCIPAL_INVESTIGATOR, Boston Children's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-30
Study Completion Date2027-09-15

Study Record Updates

Study Start Date2020-11-30
Study Completion Date2027-09-15

Terms related to this study

Additional Relevant MeSH Terms

  • Atopic Dermatitis